KLP Kapitalforvaltning’s Apellis Pharmaceuticals APLS Stock Holding History

KLP Kapitalforvaltning’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,200	Closed	-$652K	–	2148
2026 Q1	$652K	Hold	16,200	–	–	﹤0.01%	1281
2025 Q4	$407K	Buy	16,200 +600	+4%	+$14.1K	﹤0.01%	1511
2025 Q3	$353K	Hold	15,600	–	–	﹤0.01%	1574
2025 Q2	$270K	Buy	15,600 +2,600	+20%	+$48.1K	﹤0.01%	1644
2025 Q1	$284K	Sell	13,000 -2,800	-18%	-$77.3K	﹤0.01%	1585
2024 Q4	$504K	Buy	+15,800	New	+$475K	﹤0.01%	1380

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

KLP Kapitalforvaltning's APLS Position: Q2 2026 in Review

KLP Kapitalforvaltning sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 16,200 shares — an estimated $652K sold.

KLP Kapitalforvaltning first reported a position in APLS in Q4 2024 and held it in 6 quarters. The position peaked at $652K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

KLP Kapitalforvaltning reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
KLP Kapitalforvaltning sold 16,200 Apellis Pharmaceuticals shares in Q2 2026, an estimated $652K.
KLP Kapitalforvaltning first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 6 quarters.
KLP Kapitalforvaltning's Apellis Pharmaceuticals position peaked at $652K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.